Author/Authors :
Nagaharu, Keiki Department of Hematology and Oncology - Suzuka General Hospital - Yamanohana - Yasuzuka - Suzuka - Mie Prefecture , Japan , Ikemura, Kenji DepartmentofPharmacy - MieUniversityHospital - Edobashi - Tsu - MiePrefecture , Japan , Yamashita, Yoshiki Department of Hematology and Oncology - Mie University Graduate School of Medicine - Edobashi - Tsu - Mie Prefecture , Japan , Oda, Hiroyasu Department of Hematology and Oncology - Mie University Graduate School of Medicine - Edobashi - Tsu - Mie Prefecture , Japan , Ishihara, Mikiya Department of Hematology and Oncology - Mie University Graduate School of Medicine - Edobashi - Tsu - Mie Prefecture , Japan , Sugawara, Yumiko Department of Hematology and Oncology - Mie University Graduate School of Medicine - Edobashi - Tsu - Mie Prefecture , Japan , Tamaru, Satoshi Department of Hematology and Oncology - Mie University Graduate School of Medicine - Edobashi - Tsu - Mie Prefecture , Japan , Mizuno, Toshiro Department of Hematology and Oncology - Mie University Graduate School of Medicine - Edobashi - Tsu - Mie Prefecture , Japan , Katayama, Naoyuki Department of Hematology and Oncology - Mie University Graduate School of Medicine - Edobashi - Tsu - Mie Prefecture , Japan
Abstract :
Over the past decades, 5-Fluorouracil (5-FU) has been widely used to treat several types of carcinoma, including esophagealsquamous cell carcinoma. In addition to its common side effects, including diarrhea, mucositis, neutropenia, and anemia, 5-FU treatment has also been reported to cause hyperammonemia. However, the exact mechanism responsible for 5-FU-inducedhyperammonemia remains unknown. We encountered an esophageal carcinoma patient who developed hyperammonemia whenreceiving 5-FU-containing chemotherapy but did not exhibit any of the other common adverse effects of 5-FU treatment. Atthe onset of hyperammonemia, laboratory tests revealed high dihydropyrimidine dehydrogenase (DPD) activity and rapid 5-FUclearance. Our findings suggested that 5-FU hypermetabolism may be one of the key mechanisms responsible for hyperammonemiaduring 5-FU treatment
Keywords :
Hyperammonemia Associated , High Dihydropyrimidine Dehydrogenase Activity , DPD , Over the past decades, 5-Fluorouracil (5-FU)
